-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since zanubrutinib independently developed by BeiGene was approved by the US FDA in November 2019, local innovative drug companies have gradually emerged with enthusiasm for going overseas, and more and more companies have begun to embark on the road of internationalization
.
Today, this gradually growing team includes not only local companies such as Hengrui Medicine, BeiGene, and Innovent Bio, but also emerging pharmaceutical companies such as Tianjing Bio, Jiakesi, Ruige Medicine, and Clover Bio
.
From the perspective of the mode of local pharmaceutical companies going overseas, "License out" is the main mode.
In the past year, many innovative drugs in popular fields such as PD-1 and ADC are going overseas, and a number of license out cooperation projects have been launched, involving Rongchang Bio, Rongchang Bio, Junshi Bio, Hengrui Medicine,
etc.
Among them, at the end of 2021, BeiGene announced a cooperation agreement with Novartis to obtain the main overseas rights and interests of BeiGene's TIGIT antibody Ociperlimab (BGB-A1217)
.
This is another major cooperation between BeiGene and Novartis after the PD-1 mAb Baizean
.
According to relevant statistics, in 2021, there will be 53 national innovative drug license-out projects, a year-on-year increase of 120.
8%
.
Behind many cooperations, it can also be seen that overseas markets have improved the strength of China's innovative drugs
.
Guohai Securities once pointed out in a research report that domestic innovative drug companies have continuously enhanced their own research and development capabilities and will focus on overseas markets
.
On the one hand, the license out model can save money in the early stage of the company's development and quickly realize commercialization benefits with the help of the international pharmaceutical company's sales network; on the other hand, it can provide management experience for the comprehensive internationalization of the company's future products
.
The industry predicts that with the improvement of China's innovative drug research and development capabilities, the intensified competition in the domestic pharmaceutical market, and the promotion of centralized procurement and medical insurance cost control, 2022 will be the year for local pharmaceutical companies to accelerate their overseas expansion
.
It is worth mentioning that while pharmaceutical companies see opportunities to go overseas, the industry also points out a major challenge, that is, not all pharmaceutical companies can successfully go overseas.
They believe that the future of commercial cooperation between pharmaceutical companies may be a big wave..
As far as the "License out" model is concerned, although local pharmaceutical companies can reduce R&D risks and costs through this shortcut, and if successful, they can also obtain returns from domestic and overseas markets, but not all innovative products can be recognized
.
In April 2021, Merck announced the termination of its cooperation with Oncor Immunization
.
Prior to this, Merck pre-acquired the development of Oncor Immune's CD24Fc (MK-7110) for $425 million
.
As for the reason for the termination, the main reason is that Oncor Immunization still needs to submit other data to support the FDA's emergency use authorization application.
Merck expects that after the supplementary study, the product will be launched in the first half of 2022
.
Considering the increasing number of competitors and the higher uncertainty brought about by the time delay, Merck made the decision to "break up"
.
From the perspective of domestic innovative drugs going overseas, although some domestic innovative drugs have been approved by the FDA, there are also some cases of premature failure.
For example, Kanghong Pharmaceutical stopped the global multi-center clinical trial of Conbercept ophthalmic injection.
100,000,000 research and development bamboo baskets are empty; Wanchun Pharmaceutical's punablin, the stock price plummeted 60% due to the rejection of the FDA listing
.
It can be seen from the above cases that the FDA has strict requirements for clinical trial data, and pharmaceutical companies need to have abundant and diverse clinical data to prove the stability of the drug
.
Therefore, local innovative drugs still need to face various considerations such as quality and strategy, and may enter the stage of big waves in the future
.
.
Today, this gradually growing team includes not only local companies such as Hengrui Medicine, BeiGene, and Innovent Bio, but also emerging pharmaceutical companies such as Tianjing Bio, Jiakesi, Ruige Medicine, and Clover Bio
.
From the perspective of the mode of local pharmaceutical companies going overseas, "License out" is the main mode.
In the past year, many innovative drugs in popular fields such as PD-1 and ADC are going overseas, and a number of license out cooperation projects have been launched, involving Rongchang Bio, Rongchang Bio, Junshi Bio, Hengrui Medicine,
etc.
Among them, at the end of 2021, BeiGene announced a cooperation agreement with Novartis to obtain the main overseas rights and interests of BeiGene's TIGIT antibody Ociperlimab (BGB-A1217)
.
This is another major cooperation between BeiGene and Novartis after the PD-1 mAb Baizean
.
According to relevant statistics, in 2021, there will be 53 national innovative drug license-out projects, a year-on-year increase of 120.
8%
.
Behind many cooperations, it can also be seen that overseas markets have improved the strength of China's innovative drugs
.
Guohai Securities once pointed out in a research report that domestic innovative drug companies have continuously enhanced their own research and development capabilities and will focus on overseas markets
.
On the one hand, the license out model can save money in the early stage of the company's development and quickly realize commercialization benefits with the help of the international pharmaceutical company's sales network; on the other hand, it can provide management experience for the comprehensive internationalization of the company's future products
.
The industry predicts that with the improvement of China's innovative drug research and development capabilities, the intensified competition in the domestic pharmaceutical market, and the promotion of centralized procurement and medical insurance cost control, 2022 will be the year for local pharmaceutical companies to accelerate their overseas expansion
.
It is worth mentioning that while pharmaceutical companies see opportunities to go overseas, the industry also points out a major challenge, that is, not all pharmaceutical companies can successfully go overseas.
They believe that the future of commercial cooperation between pharmaceutical companies may be a big wave..
As far as the "License out" model is concerned, although local pharmaceutical companies can reduce R&D risks and costs through this shortcut, and if successful, they can also obtain returns from domestic and overseas markets, but not all innovative products can be recognized
.
In April 2021, Merck announced the termination of its cooperation with Oncor Immunization
.
Prior to this, Merck pre-acquired the development of Oncor Immune's CD24Fc (MK-7110) for $425 million
.
As for the reason for the termination, the main reason is that Oncor Immunization still needs to submit other data to support the FDA's emergency use authorization application.
Merck expects that after the supplementary study, the product will be launched in the first half of 2022
.
Considering the increasing number of competitors and the higher uncertainty brought about by the time delay, Merck made the decision to "break up"
.
From the perspective of domestic innovative drugs going overseas, although some domestic innovative drugs have been approved by the FDA, there are also some cases of premature failure.
For example, Kanghong Pharmaceutical stopped the global multi-center clinical trial of Conbercept ophthalmic injection.
100,000,000 research and development bamboo baskets are empty; Wanchun Pharmaceutical's punablin, the stock price plummeted 60% due to the rejection of the FDA listing
.
It can be seen from the above cases that the FDA has strict requirements for clinical trial data, and pharmaceutical companies need to have abundant and diverse clinical data to prove the stability of the drug
.
Therefore, local innovative drugs still need to face various considerations such as quality and strategy, and may enter the stage of big waves in the future
.
